Market Overview:
The global neurodegenerative disease market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as increasing prevalence of neurodegenerative diseases, rising geriatric population, and increasing research and development expenditure on neurodegenerative diseases. However, the high cost of treatment is a major restraint for the growth of this market. Based on type, the global neurodegenerative disease market is segmented into NMDA receptor antagonists, SSRIs (selective serotonin reuptake inhibitors), dopamine inhibitors, and others (beta blockers and cholinergic drugs). The NMDA receptor antagonist segment is expected to grow at a CAGR of 8% from 2018 to 2030. This growth can be attributed to the growing awareness about these drugs among physicians and patients owing to their better safety profile as compared with other classes of drugs used for treating neurodegenerative diseases. Based on application, the global Neurodegeneration Disease Market is segmented into Parkinson’s disease, Huntington’s disease amyotrophic lateral sclerosis (ALS), Alzheimer’s disease,.
Product Definition:
Neurodegenerative diseases are a group of progressive brain disorders that cause the death of nerve cells in the brain. These include conditions like Alzheimer's disease, Parkinson's disease, and Huntington's disease. The loss of these cells can lead to problems with movement, memory, thinking, and emotions. Neurodegenerative diseases can be fatal and there is no known cure for them.
NMDA:
N-methyl-D-aspartate (NMDA) is an amino acid derivative that acts as a glutamate receptor. It has been found to be the most active compound in treating neurodegenerative diseases such as Alzheimer's, Parkinson's and Schizophrenia. NMDA is also used in the treatment of stroke, brain cancer and hydrocephalus.
SSRIs:
SSRIs are selective serotonin receptor inhibitors. They are used to treat depression and anxiety disorders. SSRIs block the re-absorption of serotonin by certain nerve cells in the brain, which enhances the action of serotonergic neurons.
The global neurodegenerative disease market is expected to witness significant growth over the forecast period owing to increasing prevalence.
Application Insights:
The other application segment includes the research sector which comprises academic research institutes and private companies. Academic research institutes include universities, colleges and high schools that conduct in-vivo as well as in-vitro studies for neurodegenerative diseases. Companies involved in drug discovery and development are also considered to be part of the market players.
Companies such as Biogen, Inc., Eisai Co., Ltd., Enzon Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd.; Eli Lilly & Co.; Janssen Pharmaceuticals, LP; Pfizer; sanofi aventis; Sunovion S.A.; Teva Pharmaceuticals Industries Ltd.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of industry players, favorable reimbursement policies, and increasing healthcare expenditure are some factors driving the regional market. In addition, growing awareness about neurodegenerative diseases and availability of effective treatment methods are expected to further fuel growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income levels and improving healthcare infrastructure in emerging countries such as China and India. Furthermore, an increase in research funding for neurological disorders coupled with government initiatives aimed at reducing disease burden is also likely to contribute toward regional demand during the same period (2018-2030). ‘’ ‘’ ‘’ ⑔ NeuroSolutions Ltd., 2016; Parkinson's UK Ltd., 2016; Alzheimer's Australia Inc.
Growth Factors:
- Increasing aging population: The global population is aging at an unprecedented rate, and this is particularly true for the neurodegenerative disease market. As people age, their risk of developing a neurodegenerative disease increases. This growing population provides a large potential patient pool for drugmakers to target.
- Advances in technology: Technological advances are helping researchers learn more about the causes of neurodegenerative diseases and develop new treatments for them. For example, advances in brain imaging have allowed scientists to better understand how different diseases progress in the brain over time. This knowledge is helping to improve diagnosis and treatment options for patients.
- Increased awareness: There has been an increased awareness of neurodegenerative diseases in recent years, thanks largely to high-profile campaigns by organizations like Alzheimer’s Disease International (ADI) and the Michael J Fox Foundation (MJFF). This increased awareness is raising public demand for better treatments and driving research funding towards finding new therapies for these conditions..
Scope Of The Report
Report Attributes
Report Details
Report Title
Neurodegenerative Disease Market Research Report
By Type
NMDA, SSRIs, Dopamine Inhibitors
By Application
Parkinson’s Disease, Huntington Disease, Amyotrophic Lateral Sclerosis, Alzheimer’s Disease
By Companies
Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA, UCB, Boehringer Ingelheim, Sanofi, GlaxoSmithKline
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Neurodegenerative Disease Market Report Segments:
The global Neurodegenerative Disease market is segmented on the basis of:
Types
NMDA, SSRIs, Dopamine Inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Parkinson’s Disease, Huntington Disease, Amyotrophic Lateral Sclerosis, Alzheimer’s Disease
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Pfizer
- Merck Serono
- Biogen Idec
- TEVA
- UCB
- Boehringer Ingelheim
- Sanofi
- GlaxoSmithKline
Highlights of The Neurodegenerative Disease Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- NMDA
- SSRIs
- Dopamine Inhibitors
- By Application:
- Parkinson’s Disease
- Huntington Disease
- Amyotrophic Lateral Sclerosis
- Alzheimer’s Disease
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Neurodegenerative Disease Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Neurodegenerative diseases are a group of conditions that cause progressive damage to the brain and spinal cord. They can be caused by a number of factors, including age, genetics, and exposure to toxins or chemicals. Symptoms may include memory loss, difficulty walking or speaking, problems with coordination or balance, and seizures. Some neurodegenerative diseases are fatal within a few years; others may eventually lead to complete disability.
Some of the major players in the neurodegenerative disease market are Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA, UCB, Boehringer Ingelheim, Sanofi, GlaxoSmithKline.
The neurodegenerative disease market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Neurodegenerative Disease Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Neurodegenerative Disease Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Neurodegenerative Disease Market - Supply Chain
4.5. Global Neurodegenerative Disease Market Forecast
4.5.1. Neurodegenerative Disease Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Neurodegenerative Disease Market Size (000 Units) and Y-o-Y Growth
4.5.3. Neurodegenerative Disease Market Absolute $ Opportunity
5. Global Neurodegenerative Disease Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Neurodegenerative Disease Market Size and Volume Forecast by Type
5.3.1. NMDA
5.3.2. SSRIs
5.3.3. Dopamine Inhibitors
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Neurodegenerative Disease Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Neurodegenerative Disease Market Size and Volume Forecast by Application
6.3.1. Parkinsons Disease
6.3.2. Huntington Disease
6.3.3. Amyotrophic Lateral Sclerosis
6.3.4. Alzheimers Disease
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Neurodegenerative Disease Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Neurodegenerative Disease Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Neurodegenerative Disease Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Neurodegenerative Disease Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Neurodegenerative Disease Demand Share Forecast, 2019-2026
9. North America Neurodegenerative Disease Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Neurodegenerative Disease Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Neurodegenerative Disease Market Size and Volume Forecast by Application
9.4.1. Parkinsons Disease
9.4.2. Huntington Disease
9.4.3. Amyotrophic Lateral Sclerosis
9.4.4. Alzheimers Disease
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Neurodegenerative Disease Market Size and Volume Forecast by Type
9.7.1. NMDA
9.7.2. SSRIs
9.7.3. Dopamine Inhibitors
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Neurodegenerative Disease Demand Share Forecast, 2019-2026
10. Latin America Neurodegenerative Disease Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Neurodegenerative Disease Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Neurodegenerative Disease Market Size and Volume Forecast by Application
10.4.1. Parkinsons Disease
10.4.2. Huntington Disease
10.4.3. Amyotrophic Lateral Sclerosis
10.4.4. Alzheimers Disease
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Neurodegenerative Disease Market Size and Volume Forecast by Type
10.7.1. NMDA
10.7.2. SSRIs
10.7.3. Dopamine Inhibitors
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Neurodegenerative Disease Demand Share Forecast, 2019-2026
11. Europe Neurodegenerative Disease Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Neurodegenerative Disease Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Neurodegenerative Disease Market Size and Volume Forecast by Application
11.4.1. Parkinsons Disease
11.4.2. Huntington Disease
11.4.3. Amyotrophic Lateral Sclerosis
11.4.4. Alzheimers Disease
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Neurodegenerative Disease Market Size and Volume Forecast by Type
11.7.1. NMDA
11.7.2. SSRIs
1.7.3. Dopamine Inhibitors
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Neurodegenerative Disease Demand Share, 2019-2026
12. Asia Pacific Neurodegenerative Disease Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Neurodegenerative Disease Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Neurodegenerative Disease Market Size and Volume Forecast by Application
12.4.1. Parkinsons Disease
12.4.2. Huntington Disease
12.4.3. Amyotrophic Lateral Sclerosis
12.4.4. Alzheimers Disease
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Neurodegenerative Disease Market Size and Volume Forecast by Type
12.7.1. NMDA
12.7.2. SSRIs
12.7.3. Dopamine Inhibitors
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Neurodegenerative Disease Demand Share, 2019-2026
13. Middle East & Africa Neurodegenerative Disease Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Neurodegenerative Disease Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Neurodegenerative Disease Market Size and Volume Forecast by Application
13.4.1. Parkinsons Disease
13.4.2. Huntington Disease
13.4.3. Amyotrophic Lateral Sclerosis
13.4.4. Alzheimers Disease
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Neurodegenerative Disease Market Size and Volume Forecast by Type
13.7.1. NMDA
13.7.2. SSRIs
13.7.3. Dopamine Inhibitors
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Neurodegenerative Disease Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Neurodegenerative Disease Market: Market Share Analysis
14.2. Neurodegenerative Disease Distributors and Customers
14.3. Neurodegenerative Disease Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novartis
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Merck Serono
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Biogen Idec
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. TEVA
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. UCB
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Boehringer Ingelheim
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Sanofi
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. GlaxoSmithKline
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
